Work

Pathologic complete response following salvage surgery after lazertinib treatment in advanced EGFR-mutated lung adenocarcinoma: case report and literature review

Year: 2025

Type: article

Abstract: Background: Salvage surgery following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor therapy is a viable treatment option for selected patients with initially unresectable non-small cell lung cancer (NSCLC) harboring EGFR mutations. Case Description: We herein describe a 63-year-old man who presented to the emergency department with a 1-week history of speech disturbance and was diagnosed with clinical stage T1cN2M1b, IVA NSCLC with an EGFR exon 21 L858R mutation. The patient underwent brain tumor resection followed by stereotactic radiosurgery and was treated with palliative lazertinib for 6 months. A radiologic complete response was observed in follow-up imaging, and salvage surgery was recommended after multidisciplinary consultation. Right upper lobectomy with mediastinal lymph node dissection revealed a pathologic complete response with no residual tumor cells. The patient remained disease-free for 1 year following lazertinib treatment. Conclusions: This case suggests that salvage surgery after treatment with lazertinib may be a safe and effective approach for NSCLC with common EGFR mutations.

Source: Translational Lung Cancer Research

DOI: 10.21037/tlcr-24-893

Authors: Chanmi Kim, Jongsoo Park, Jang Hoon Lee, Seong Yong Jeong, June Hong Ahn

Institutions: Yonsei University, Yonsei University Health System, Yeungnam University, Yeungnam University Medical Center, Yeungnam University College

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4407998146

FWCI:

Cites:

Cited by:

Related to: 10